GlassScriptPhysician profile
Ralph W Baucum
NPI 1295735793
$4,851.68
in general payments reported to CMS, 2019-2025
25 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $502 · 2021: $470 · 2022: $565 · 2023: $683 · 2024: $1,102 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,343.47 | 2019-2025 | Watchman, General - Vascular Intervention, General - Tachy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $657.14 | 2019-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $297.89 | 2024-2025 | Assure Wcd |
| Medtronic, INC. | $288.00 | 2022-2024 | Micra, Corevalve Evolut R, Ffrangio |
| Sanofi-Aventis U.S. LLC | $126.89 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $124.27 | 2023-2025 | Verquvo, Capvaxive |
| Edwards Lifesciences Corporation | $120.70 | 2019 | |
| Abiomed | $110.90 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $105.37 | 2022-2024 | Xarelto |
| Abbott Laboratories | $101.39 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Diamondback Coronary |
| E.R. Squibb & Sons, L.L.C. | $86.45 | 2020-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $75.19 | 2025 | |
| Atricure, INC. | $66.54 | 2019 | |
| Amgen INC. | $58.46 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.30 | 2019-2023 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.37 | 2024-2025 | Wegovy |
| Pfizer INC. | $35.06 | 2024-2025 | |
| Itamar Medical INC | $22.42 | 2025 | Watchpatone |
| Lilly USA, LLC | $22.37 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $21.81 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.50 | 2023 | Arcalyst |
| Lundbeck LLC | $19.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.28 | 2024 | Farxiga |
| Philips North America LLC | $14.81 | 2025 | Ecc Solutions |
| Gilead Sciences, INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Baucum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.